Overslaan en naar de inhoud gaan

HIPRA launches two unique vaccines against Bovine Respiratory Disease (BRD) in Colombia

Runderen

At this event, Dr Ramón Armengol, Associate Professor at Lleida University, gave a presentation entitled “Early diagnosis and management of bovine respiratory disease (BRD) in replacement heifers: from birth to first calving" so that he could share with the audience his experience in terms of BRD diagnosis and management in dairy heifers.

Antonio Souto (Regional Technical Marketing Manager South America) then presented HIPRABOVIS® SOMNI/Lkt, a vaccine that provides protection against 2 pasteurella species), reducing clinical signs by 50%, lung lesions by 50% and antibiotic use five-fold.

In addition, Vincent Robles (Reproductive Ruminants Brand Manager) presented to the audience the global solution proposed by HIPRA for the control of 3 important viruses (BVD, BRSV, PI3) -which not only cause BRD but also reproductive disorders- a compound of the trivalent vaccine HIPRABOVIS®BALANCE and of an innovative diagnostic tool, BOVIRESPcheck, to identify viruses by PCR.

This new landmark positions HIPRA as the first global pharmaceutical company to offer its customers in Colombia a global approach to respiratory diseases in cattle.

bovine-respiratory-disease-vaccines-brd-in-colombia.jpeg

At this event, Dr Ramón Armengol, Associate Professor at Lleida University, gave a presentation entitled “Early diagnosis and management of bovine respiratory disease (BRD) in replacement heifers: from birth to first calving" so that he could share with the audience his experience in terms of BRD diagnosis and management in dairy heifers.

Antonio Souto (Regional Technical Marketing Manager South America) then presented HIPRABOVIS® SOMNI/Lkt, a vaccine that provides protection against 2 pasteurella species), reducing clinical signs by 50%, lung lesions by 50% and antibiotic use five-fold.

In addition, Vincent Robles (Reproductive Ruminants Brand Manager) presented to the audience the global solution proposed by HIPRA for the control of 3 important viruses (BVD, BRSV, PI3) -which not only cause BRD but also reproductive disorders- a compound of the trivalent vaccine HIPRABOVIS®BALANCE and of an innovative diagnostic tool, BOVIRESPcheck, to identify viruses by PCR.

This new landmark positions HIPRA as the first global pharmaceutical company to offer its customers in Colombia a global approach to respiratory diseases in cattle.